title: AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation.
abstract: OBJECTIVE
  Genetic variation may influence women's response to ovarian stimulation therapy. The purpose of this study was to investigate any effects of genetic variants in the anti-Müllerian hormone (AMH) and AMH type II receptor genes on ovarian response/treatment outcomes and on current markers of ovarian reserve in individuals undergoing in vitro fertilisation (IVF) treatment.
  
  
  METHODS
  In this prospective observational study, we genotyped the AMH c.146G>T, p.(Ile49Ser) and AMHR2 -482A>G variants in 603 unrelated women undergoing their first cycle of controlled ovarian stimulation for IVF and ICSI (intracytoplasmic sperm injection) using gonadotrophins at a tertiary referral centre for reproductive medicine. Pelvic ultrasound and blood hormone levels were taken on days 2-3 of the cycle. Genotypes were determined using TaqMan allelic discrimination assay. Regression analysis was performed to assess the relationship between the genotypes and the ovarian reserve markers (FSH, AMH, antral follicle count) and the early outcomes of response (number of oocytes retrieved and gonadotropin dose) as well as the treatment outcome (live birth).
  
  
  RESULTS
  There were no significant associations between the variants AMH c.146G>T and AMHR2 -482A>G with ovarian response in terms of number of oocytes retrieved (p = 0.08 and p = 0.64, respectively), live births (p = 0.28 and p = 0.52) and/or markers of ovarian reserve.
  
  
  CONCLUSIONS
  Genotyping of the AMH c.146G>T and AMHR2 -482A>G polymorphisms does not provide additional useful information as a predictor of ovarian reserve or ovarian response and treatment outcomes.
authors.affiliation: Department of Reproductive Medicine, St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.|Manchester Centre for Genomic Medicine, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, M13 9WL, UK.
authors.forename: Christian
authors.initials: C
authors.lastname: Cerra
authors.affiliation: Manchester Centre for Genomic Medicine, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, M13 9WL, UK.|Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.
authors.forename: William G
authors.initials: WG
authors.lastname: Newman
authors.affiliation: Manchester Centre for Genomic Medicine, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, M13 9WL, UK.|Clinical pathology, Mansoura University Faculty of Medicine, Mansoura, Egypt.
authors.forename: Dalia
authors.initials: D
authors.lastname: Tohlob
authors.affiliation: Manchester Centre for Genomic Medicine, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, M13 9WL, UK.|Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Byers
authors.affiliation: Clinical Embryology, Department of Reproductive Medicine, St. Mary's Hospital, Manchester, UK.
authors.forename: Gregory
authors.initials: G
authors.lastname: Horne
authors.affiliation: Department of Reproductive Medicine, St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.|Centre for Biostatistics, Institute of Population Health, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, UK.
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Roberts
authors.affiliation: Department of Reproductive Medicine, St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK. lamiya.mohiyiddeen@cmft.nhs.uk.
authors.forename: Lamiya
authors.initials: L
authors.lastname: Mohiyiddeen
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000235:genetics*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D052681:Gonadotrophs / Q000378:metabolism; D006801:Humans; D065851:Ovarian Reserve / Q000235:genetics*; D010062:Ovulation Induction / Q000379:methods*; D011110:Polymorphism, Genetic / Q000235:genetics; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D018000:Receptors, Peptide / Q000235:genetics*; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D020554:Sperm Injections, Intracytoplasmic; D016896:Treatment Outcome
chemical_list: D018000:Receptors, Peptide; D018125:Receptors, Transforming Growth Factor beta; C084621:anti-Mullerian hormone receptor; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone
keywords: Anti-Mullerian hormone; Antral follicle count; Follicle-stimulating hormone; Ovarian hyperstimulation syndrome; Ovarian response; Pharmacogenetics